Occult hepatitis B virus infection among Mexican human immunodeficiency virus-1-infected patients

Table 3 Analysis of potential risk variables associated with hepatitis B virus infection in human immunodeficiency virus-1 patients

	HBV DNA
	Positive (n = 24)n (%)	Negative (n = 25)n (%)	χ2	P value	OR	95%CI
Gender
Male	17 (71)	20 (80)	0.55	0.45	0.60	0.16-2.26
Female	7 (29)	5 (20)
Age
< 45 yr	12 (50)	12 (48)	0.02	0.88	0.92	0.30-2.83
≥ 45 yr	12 (50)	13 (52)
Seropositive for any marker (SP)
Yes	13 (54)	14 (56)	0.01	0.89	0.92	0.30-2.86
No	11 (46)	11 (44)
HIV RNA VL > 50 copies/mL
Detectable	15 (63)	4 (16)	11.15	0.001	8.75	2.26-33.79
No detectable	9 (37)	21 (84)
ARV-treatment
Yes	24 (96)	23 (96)	-	1.01	1.04	0.06-17.68
No	1 (4)	1 (4)
With TDF/FTC or 3TC
Yes	13 (54)	20 (80)	3.72	0.052	0.25	0.08-1.05
No	11 (46)	5 (20)
CD4+
< 200 cell/mm3	2 (8)	3 (12)	-	1.01	0.66	0.10-4.38
> 200 cell/mm3	22 (92)	22 (88)

¹Fisher’s exact test;

²α = 95%, β = 80%, OR = 0.29 with the same percentages.